Pharmalittle: Will EMA move to Slovakia? Roche gets a big approval

first_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. [email protected] What’s included? Log In | Learn More @Pharmalot By Ed Silverman Nov. 17, 2017 Reprints Alex Hogan/STAT GET STARTED Pharmalot And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda kicks off with another installment in our “let’s-see-them-before-they-die” concert series, but then is likely to ease into a series of overdue naps. And what about you? There is a holiday approaching on this side of the pond, so perhaps this is a chance to plan your menu or determine how to decline an unwanted invitation. You could enjoy the great outdoors. Or simply do nothing. Well, whatever your choices, have a grand time. But be safe. Enjoy, and see you soon …Bratislava, Slovakia, and Milan, Italy, have emerged as front-runners to host the European Medicines Agency after Brexit, the Financial Times informs us. European Union ministers from 27 countries will vote in a secret ballot on Nov. 20 on a new home for the regulator. However, an EMA survey of employees found that more than 70 percent of its staff may leave if the agency is moved to the Slovak capital.center_img What is it? Pharmalittle: Will EMA move to Slovakia? Roche gets a big approval Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Ed Silverman STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. About the Author Reprints Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Tags opioidspharmaceuticalspharmalittlepolicySTAT+last_img

Posts Tagged with… , , , , , , , , , , ,

Write a Comment

Your email address will not be published. Required fields are marked *